MarketPulse

psilocybin

3 articles
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Psyence BioMed Executes Put Option, Issues $5M in Shares to PsyLabs

Psyence BioMed issues $5M in shares to PsyLabs via put option exercise, giving PsyLabs ~50% ownership and strengthening supply chain for psychedelic pharmaceuticals.
PBMPBMWWsupply chainshareholder dilution
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Psyence BioMed Secures Psychedelic Supply via Put Option Deal with PsyLabs

Psyence BioMed secures pharmaceutical-grade psychedelic supply through put option deal with PsyLabs, ensuring reliable access while maintaining liquidity for clinical development.
PBMPBMWWsupply chainpsilocybin